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Abstract
Background: In general the health of methadone clients has been found to be poorer than that
of the general population. In New Zealand specialist drug services are not funded to provide
primary healthcare services. Many health conditions could potentially be managed by community
pharmacists who have frequent contact with this client group. This study sought to explore the
health problems suffered by methadone clients, who they sought help from, and the potential for
greater involvement of pharmacists.
Methods: Self-completion questionnaire of methadone maintenance clients managed in specialist
care in Auckland, New Zealand.
Results: The most common health problem experienced by these clients in the past three months
was sweating (70.0%), and more than half of the respondents also reported experiencing headache,
fatigue and depression. The least frequently experienced conditions were hay fever (12.9%) and
abscesses (12.1%). Respondents indicated that the top three choices from whom they would seek
help were GP (56.7%), the client's partner (31.6%) and community pharmacists (27.9%). Barriers
to seeking help from pharmacists included issues around cost, perceptions of pharmacist
knowledge and skills, privacy and confidentiality.
Conclusion: Methadone clients in this study indicated that they suffered a number of general
health problems, and in many cases were likely to seek help from a GP or their own partner, before
seeking help from pharmacists. However, for over one quarter of respondents the pharmacist was
in the top three from whom they would seek advice. Any barriers towards consulting pharmacists,
in the main seem to be resolvable.
Background
In general the health of drug users has been found to be
poorer than that of the general population. Ryan and
White [1] noted that the health status of clients entering a
public methadone programme in Australia was generally
poorer on measures of physical and psychological health
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than that of the general population. A New Zealand study
of self-assessed health status (using SF36) found this was
significantly worse in methadone patients than the New
Zealand population mean score, and 75% of the sample
had engaged in help-seeking activities around general
health issues for themselves [2]. With regard to psycholog-
ical health, Brienza et al found that 42% of methadone
patients met criteria for major depression [3].
Research focusing on more specific aspects of methadone
client health has pointed to significant poor health and
morbidity. In a study of nutrition, methadone clients were
found to prefer sweet foods and to consume in excess of
the daily recommended proportion of mono and disac-
charides [4]. A similar finding was noted in Australia
where women in methadone treatment had a high sugar
and low fibre intake [5], and Best and colleagues noted
that among methadone patients in their study, 3%
reported no "eating events" in the previous three days and
27% had eaten no cooked meals [6]. Other health prob-
lems which particularly affect methadone clients include
sweating and constipation [7], sleep disturbances [8,9]
and dental problems [10-12]. Lack of treatment for such
problems may result in increased health-related harm to
drug users.
In New Zealand, community pharmacists have long been
involved in the provision of harm reduction services to
drug misusers – either through their role in the provision
of needle exchange [13,14] or through the dispensing of
methadone prescriptions for the management of opiate
dependence. In 2003 it was estimated that around 1 in 5
community pharmacies provided a needle exchange serv-
ice (personal communication – Charles Henderson) and
approximately a half of community pharmacists work in
pharmacies which dispensed methadone prescriptions
(personal communication – Linda Bryant). These figures
are similar to those found in England and Wales [15] and
represent a major contribution of the profession to pro-
viding support and healthcare to drug users.
The provision of these services brings community phar-
macists into frequent contact with injecting drug users
and opiate dependent patients [16], thus creating poten-
tial opportunities for further intervention around a wide
range of issues. For example, many needle exchange phar-
macies provide written and verbal information on testing
for blood borne viruses, accessing treatment, avoiding
overdose and safer injecting [17]. Such interventions are
obvious in relation to the client group. However, it may
be argued that community pharmacists having success-
fully taken on such roles, have tended to focus on the drug
user in terms of their drug use and route of use, and have
possibly paid less attention to the general health issues of
drug users. Such health problems may be the same kind of
health problems suffered by the general population (e.g.
coughs, colds, headache etc) or may be directly related to
their drug use. There is however, the issue of stigmatisa-
tion of drug users, in which legitimate requests for over-
the-counter remedies for problems such as pain, coughs
and colds may be treated with suspicion, as many of these
products contain substances liable to abuse [18,19].
This present study has sought to explore some of these
issues in a group of methadone clients at Auckland Meth-
adone Service (AMS), New Zealand. AMS provides a
methadone maintenance, methadone reduction and
methadone detoxification service to opiate dependent cli-
ents in a catchment area of almost 1.2 million [20-22]. At
the time of conducting the study (Mid January to mid
April 2005), AMS was funded to provide services for 989
methadone clients. Around three quarters are managed
within the service having their methadone prescribed to
them by AMS medical officers and seeing a case manager
at least once every three months at a Community Alcohol
and Drug service (CADS) clinic of their choice, the
remaining quarter managed in primary care having their
methadone prescribed by authorised general practitioners
and routinely accessing AMS for further consultation. GP
managed clients have been stabilised within the service
and are considered to be more stable with regard to drug
use and behaviour than those managed within AMS.
AMS is not funded to provide general healthcare to clients,
so those managed within the service who do not have a
GP to consult about their health may need to use other
health professionals or lay people for help with such
problems. In addition, in New Zealand, GP care incurs a
cost to the patient at the point of access and may be seen
as a barrier to accessing treatment; treatment through AMS
is free of charge.
Another health professional trained to provide advice,
treatment and referral is the community pharmacist. Con-
sulting the pharmacist is free of charge and no appoint-
ment is needed. However, if medicines are required they
must either be purchased from the pharmacy or obtained
on prescription, both of which will incur a cost. In theory,
with methadone clients seeing pharmacists several times a
week to collect their prescribed methadone there are
numerous opportunities for clients to consult pharmacists
about their health, or for pharmacists to proactively
enquire about health issues known to be of particular
problem for methadone clients.
There are a number of potential barriers to methadone cli-
ents seeking healthcare from community pharmacists.
Research into drug users' views of accessing methadone
and needle exchange services through pharmacies have
described several barriers. These include the attitudes ofHarm Reduction Journal 2005, 2:25 http://www.harmreductionjournal.com/content/2/1/25
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the pharmacist and staff and lack of privacy [23-25]. In
addition, many pharmacists report not wishing to provide
these services [15,16] and thus maybe unlikely to be will-
ing to provide primary healthcare services to drug users.
In New Zealand, no data exist about the incidence of gen-
eral health problems suffered by methadone patients, nor
have the potential barriers to accessing advice and treat-
ment through community pharmacies been explored. In
order to better understand some of the issues around the
general health problems of methadone clients, whom
they access for help and treatment, and barriers to utilis-
ing community pharmacists for help and treatment, a
study was designed with the following aims:
• To review the general health problems that AMS clients
managed within the specialist services suffered in a 3
month period;
• To document the incidence of chronic medical condi-
tions;
• To explore who AMS clients turn to for advice;
• To explore whether clients utilise community pharma-
cists for this type of advice;
• To explore barriers to a greater role for community phar-
macists.
Methods
Study design
The study employed a cross sectional design, using a self-
completion questionnaire.
Sample
All AMS clients managed within specialist services, but
not those managed through authorised GP care, and who
had appointments within the next three months were
included in the study. AMS is not funded to provide gen-
eral healthcare to methadone clients, thus those managed
by GPs were not included because they already had access
to healthcare via their GP-managed methadone treatment
and thus may have biased the results.
Sampling procedure
AMS clients managed through the CADS services were
identified through the AMS database, and a list of AMS cli-
ents attending each CADS clinic on a "once every three
months" basis was provided to the admissions officers
(AOs) at each of the five CADS clinics. As a client pre-
sented for their appointment, he or she was asked whether
they would be willing to complete a brief questionnaire
either whilst waiting for their appointment or take it
home and complete it later, returning it in a prepaid enve-
lope provided for its return. Once a client had been
approached the AO ticked off the client from the list,
ensuring clients were only approached once.
This process took place between mid January and mid
April 2005, thus capturing a 3-month time period in
which, theoretically, each client would be seen by the serv-
ice. In reality, a number of clients did not make or attend
appointments, and the denominator for this study was
therefore the number of clients attending appointments
during this time period.
Questionnaire design
A self-completion quantitative questionnaire was devel-
oped to explore perceived health status and treatment-
seeking behaviour for individuals. Although other instru-
ments are available that measure heath and wellbeing
such as SF36 [26], the Quality of Wellbeing Scale [27] and
Sickness Impact Profile Scale [28], they tend to focus on
global health issues and are not designed with opiate
users in mind. The health sections of the Opiate Treat-
ment Index [29] contain a number of questions on health.
However, the instrument is designed to explore health in
a four-week period in a clinical setting, and is not
designed for self-completion. In this study, the aim was to
explore incidence of general health issues such as minor
ailments which may or may not be specific to drug use, as
a way of gauging potential for a community pharmacist
role. From this perspective a three month time period was
used, (four weeks being considered to short a period to
capture the incidence of rarer health problems), and a
selection of general health items was chosen that could be
responded to by community pharmacists, and for which
there are over-the-counter remedies available. Other more
drug-specific items were included after discussion with the
AMS clinical team, who wished to utilise the opportunity
provided by the study to collect data on the clients. The
questionnaire was reviewed by consumer advisors, AMS
medical officers and case managers. Questionnaires were
pre-piloted amongst staff and consumer advisors at
CADS, and feedback indicated it was easy to complete,
taking 5–10 minutes.
Questionnaires were anonymous – no client identifiers
were required. Health problems surveyed include general
health problems and symptoms suffered in the previous
three months (e.g. cold, indigestion, nausea, diarrhoea,
sweating, constipation, toothache, loss of appetite,
abscesses, swollen hands and feet/fluid retention), psy-
cho-neurological problems (headaches, difficulty sleep-
ing, fatigue, depression), respiratory problems (hay fever
cough, dry mouth), dry and itching eyes, and skin rashes.
The existence of chronic health problems was also
explored. Help- and treatment-seeking behaviour, barriers
to help-seeking, and substance use were also surveyed.Harm Reduction Journal 2005, 2:25 http://www.harmreductionjournal.com/content/2/1/25
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Data were entered into SPSS version 12.1, and analysed
using general frequencies. Further analysis was conducted
using appropriate parametric and non-parametric statisti-
cal tests.
Results
During the study period 715 appointments with AMS cli-
ents were scheduled, and a total of 556 clients (77.7%)
were seen at appointments. Of these 556, 335 (60.3%)
were male, 424 (76.3%) were European/Pakeha, 65
(11.7) Maori, 8 (1.4%) Pacific, 8 (1.4%) Asian and 51
(9.2%) other. Of these, 361 clients (65%) (57.9% male)
were 'offered' a questionnaire, according to the records
kept by AOs at each CADS clinic. Of these, 231 (64%)
completed and returned a questionnaire (representing
42% who had appointments). Just over half (50.2%) were
male (data missing on 14 cases), and the majority self-
identified solely as European/Pakeha (72.7%). Maori
(including those identifying as Maori and Pakeha) clients
comprised 15.5%, Pacific Islanders 1.8%, Asian 0.9% and
others 2.2% of the respondents (data missing on 16
cases). Just over half of the respondents (52.9%) stated
they had a GP with whom they could comfortably discuss
health problems (data missing on 23 cases).
Respondents had used the following substances once a
week or more frequently in the previous three months:
morphine 14.5%, cannabis 40.5%, stimulants (e.g. meth-
amphetamine) 11.5%, ecstasy 2.2%, alcohol 23.3% and
cigarettes 74.4% (data missing on 8 cases).
Table 1 provides data on self-reported chronic health
problems. The most common condition that the respond-
ents reported suffering from was hepatitis C (51.6%).
About a quarter of the respondents (24.0%) reported
mental health problems, 23.1% reported suffering from
chronic pain, and 21.3% suffered from migraine. Only
2.3% of the respondents had diabetes and none of them
reported being HIV positive.
Clients were asked to identify health problems suffered in
the last three months from a list provided (see Table 2 for
details), by ticking a box for 'yes'. A blank box was
assumed to be a negative response. The most common
health problem experienced by these clients in the past
three months was sweating (70.0%). More than half of
the respondents also reported experiencing headache,
fatigue and depression. The least frequently experienced
conditions were hay fever (12.9%) and abscesses
(12.1%). Respondents had suffered from a mean of 6.76
conditions (sd = 4.12; median = 6; mode = 4; range = 0–
19).
Clients were asked to tick up to three individuals or
groups from a list provided, that they were most likely to
ask for help when suffering from any health-related prob-
lems mentioned in Table 2, by ticking a box for 'yes'. A
blank box was assumed to be a negative response. The
most popular choices were the GP (56.7%), the client's
partner (31.6%) and community pharmacists (27.9%).
None of the respondents identified Maori health workers
nor Hapu, Iwi health kaimahi among their first three
choices. Five respondents stated that they would not seek
help from anyone apart from themselves (see Table 3).
Similarly, the respondents were then asked to identify
who else they would consider asking for advice/help (see
Table 3). Collating responses to 'who would you be most
Table 2: Health problems suffered in last 3 months* (N = 231)
N%
No health problems 3 1.3
Cold 56 24.2
Hayfever 28 12.1
Headaches 130 56.3
Indigestion 54 23.4
Cough 56 24.2
Nausea 80 34.6
Diarrhoea 39 16.9
Sweating 162 70.1
Skin rashes 49 21.2
Dry/itchy eye 36 15.6
Dry mouth 104 44.2
Constipation 105 45.5
Sleep problems 135 58.4
Toothache 108 46.8
Fatigue 117 50.6
Depression 117 50.6
Swollen hands/feet 66 28.6
Loss of appetite 90 30.9
Abscesses 32 13.9
* identified by ticking a box. No tick assumed to be not suffered from 
the problem
Table 1: Self-reported medical conditions* (N = 221)
N( % )  
Any self reported medical condition from list below 186 84.2
Hepatitis C 114 51.6
Mental health problems 53 24.0
Chronic pain 51 23.1
Migraine 47 21.3
Asthma 40 18.1
Hayfever or other allergies 36 16.3
Eczema/dermatitis 20 9.0
High blood pressure 18 8.1
Arthritis 12 5.4
Hepatitis B 12 5.4
Diabetes 5 2.3
HIV 0 0
*identified by ticking a box. No tick assumed to be not suffered from 
the conditionHarm Reduction Journal 2005, 2:25 http://www.harmreductionjournal.com/content/2/1/25
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likely to consult' and 'who else would you consult', 93%
of respondents indicated GPs, 69% community pharma-
cists and 61% AMS case managers. Around half indicated
lay people such as family, friends or partner.
Respondents were asked to indicate, from a list provided,
why they would not contact a community pharmacist for
help, by ticking a box for 'yes'. A blank box was assumed
to be a negative response (respondents could choose up to
3 reasons) – see Table 4. The most common reason for not
seeking help from a community pharmacist was financial.
The second and third most common reasons for not ask-
ing for help were that people preferred to wait for the
problem to get better, and that they believed pharmacists
did not understand their problems. In addition, 15.3% of
people would not ask a pharmacist for help as they felt
lack of privacy was an issue, and 12.4% of them had con-
cerns about confidentiality.
Respondents were also asked to indicate how many times
they had seen a GP, pharmacist, case manager, dentist,
AMS doctor or needle exchange staff for help in the previ-
ous three months. Overall the number of consultations
with health professionals was very low. Data were not
normally distributed with some individuals being high
users (e.g. 10–15 consultations in last three months), and
the majority having no consultations. With the exception
of GPs (median = 1), the median for all other health pro-
fessionals was 0 (data missing on 14 cases).
Discussion
This study represents the first published study which has
specifically explored New Zealand methadone clients' pri-
mary healthcare needs and from whom they access treat-
ment. The results indicate that this is a group that suffers
a range of health problems similar to those encountered
in the general population. Problems considered to be
associated with drug use (and opiate use in particular)
were reported by a large proportion of users – e.g. dental
problems, insomnia, depression and constipation.
Respondents also reported a high mean number of indi-
vidual health problems, indicating there is a need for pro-
vision of primary healthcare to this group. Care in
interpreting these results may however be needed for
items such as depression, which are based on self-report
and may not have actually been diagnosed.
The most likely individual to be contacted for support
with healthcare was the GP, followed by a person's part-
ner. Indeed friends and family also featured quite
strongly, possibly indicating a high reliance on the lay
health network over health professionals. Reasons for this
need to be explored further, but results from this study
indicate that for pharmacists at least, cost is a major bar-
rier – being cited by two fifths of respondents and 'waiting
until things get better' being second and a possibly proxy
for cost. In the UK, the National Health Service has intro-
duced a 'minor ailments scheme' in which community
pharmacists are able to 'prescribe' to individuals in certain
financially disadvantaged groups (though not specifically
drug users) 'over-the-counter' (OTC) treatments free of
charge [30,31]. Such a scheme might be considered for
methadone clients. However, further study needs to be
undertaken into the cost of non-treatment.
Other barriers to accessing help from pharmacists
included lack of privacy and concerns about confidential-
ity. These results echo those found in studies of drug using
Table 3: Individuals or groups most likely to be consulted with regard to health problems in Table 2. (N = 215)
Individual or group  *Most likely to consult 
(can tick up to 3)
Who else would consult 
(can tick as many as required)
N%N%
GP (doctor) 122 56.7 84 36.4
Partner 68 31.6 42 18.2
Pharmacist in chemist shop 60 27.9 95 41.1
Family/whanau1 member 47 21.9 62 26.8
AMS Case manager 45 20.9 93 40.3
Friend 43 20.0 76 32.9
Chemist shop staff 15 7.0 37 16.0
Needle exchange staff 1 0.5 17 7.4
Maori health worker 0 0.0 5 2.2
Hapu, Iwi health kaimahi2 0 0.0 2 0.9
Other (includes Alcohol and drug hotline, CADS doctor, dentist, fellow 
methadone programme client, (mental health) nurse, therapist, 
naturopath, cleric).
12 5.6 11 4.8
*(NB respondents could tick up to three from a list. Those ticking more than three were excluded from this analysis).
1Whanau is a Maori word which means "the extended family which includes the nuclear family, and aunts, uncles and cousins". http://
www.justice.govt.nz/pubs/reports/1998/maori_consultation/glossary.html
2Hapu, Iwi health kaimahi – a community worker based in a local Maori communityHarm Reduction Journal 2005, 2:25 http://www.harmreductionjournal.com/content/2/1/25
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clients in Scotland [23-25]. The issue of privacy may be
addressed by the introduction of private areas and in Scot-
land funding has been provided to pharmacists to do this
as an asset for all patients. The issue of confidentiality
needs to be addressed through client education – the
pharmacists' code of ethics specifically precludes breach
of confidentiality except in issues where a duty of care may
supersede a code of confidentiality. Nonetheless, phar-
macy staff may need to be specifically educated with
regard to this.
A number of respondents had concerns about whether
community pharmacists were knowledgeable enough to
provide such healthcare. In general with regard to minor
ailments this should not be an issue. However, there are
drug-related contextual issues that may need to be covered
in tailored, professional development programmes such
as the relationship between drug use and dental prob-
lems, managing pain with OTC products and when to
refer and the need for this requires further exploration.
Another approach to overcoming this barrier is to provide
education for methadone clients on the role of the phar-
macist and their ability to manage such health problems.
Respondents reported a high rate of use of other sub-
stances such as cannabis, tobacco and alcohol. With
regard to smoking, American studies have shown that
many methadone clients want to quit and are favourable
towards the use of nicotine-replacement-therapies (NRT)
[32]. Community pharmacists have been shown to be
effective in helping smokers to quit [33] and with appro-
priate collaboration with drug services may have an
important role to play.
A number of limitations should be taken into account in
interpreting and extrapolating results from this study. The
response rate of those who were 'offered' a questionnaire
was 65%, which is high for a survey that was unable to
employ a non-responder follow-up methodology. How-
ever, there are issues with regard to those who were not
'offered' a questionnaire – i.e. did they actually decline to
take part, or were they simply missed during a busy clinic
day. Furthermore, despite a requirement for clients to be
seen once every 3 months, only 556/715 attended
appointments. It maybe that those not attending are very
stable on treatment; however, there may also be some
who did not attend because they were unwell, and as such
this potential bias needs to be taken into account. Thus,
while a 65% response rate from those given a question-
naire was high, generalisations to the whole of the meth-
adone clients in the study should be made with caution.
The sample of respondents also under-represents males
and slightly over-represents Maori when compared with
data for all attendees during the study time period.
In designing the study it was initially envisaged that only
those 'minor ailments' that might be attended to by com-
munity pharmacists would be included in the study.
However, feedback from AMS staff indicated that they
would like a number of other conditions or symptoms
included such as depression, loss of appetite and
abscesses – issues much less likely to be managed in com-
munity pharmacy. When asking respondents whom they
would be most likely to contact about any of these health
issues, and with high proportions reporting they suffered
from depression for example, the results are thus likely to
be skewed away from the community pharmacist. Ideally,
respondents would have been asked whom they would
have consulted for each condition, but this would have
made the questionnaire too complex and may possibly
have compromised a good response rate.
Conclusion
Methadone clients in this study indicated that they suf-
fered a number of general health problems, but in many
cases were likely to seek help from a GP or their own part-
ner, before seeking help from pharmacists. They also indi-
cated that they might simply wait for problems to resolve.
However, a significant proportion cited the community
pharmacist as a person whom they would be most likely
to contact, and the barriers towards consulting pharma-
cists in the main, are resolvable. In particular issues
around cost, pharmacist training and reorientation of
premises to allow for improved privacy need to be taken
into consideration when attempting to expand a harm
reduction role for pharmacists with this client group. Fur-
thermore, there seems to be a need to address clients'
beliefs about the community pharmacist's role in the pro-
vision of healthcare.
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Table 4: Reasons for AMS clients not seeking treatment or 
advice from a community pharmacist when suffering from health 
problems identified in Table 2 (N = 208)
N%
Cannot afford it 88 42.1
Prefer to wait until the problem gets better 77 36.8
Believing pharmacist lacks understanding about client 
health problems
38 18.2
Not private enough 32 15.3
Concerns about confidentiality 26 12.4
Prefer to seek treatment and advice from someone else 25 12.0
Time consuming 13 6.2
Have medicine at home 9 4.3
(NB respondents could tick up to three from a list. Those ticking 
more than three were excluded from this analysis).
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